Zhang Shu, Zeng Xiaoning, Wei Jifu, Li Shan, He Shaoheng
Clinical Research Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Recent Pat Inflamm Allergy Drug Discov. 2010 Jun;4(2):130-7. doi: 10.2174/187221310791163116.
The prevalence of allergic diseases has increased dramatically in recent decades. Holding patents is one of the means to protect good anti-allergy products. However, little is known of anti-allergy patent situation in China. The paper summarized and analyzed anti-allergy patents issued in China from January 1988 to September 2008. A total of 789 anti-allergy patents have been granted in China during the 20 years. China, European countries, USA, Japan and other countries possesses 44%, 21%, 19%, 12% and 4% of all of these anti-allergy patents respectively. Interestingly, 88% anti-allergy patents issued to Chinese are held by civilians, whereas vast majority of the patents issued to foreigners were held by pharmaceutical companies. All anti-allergy patents are focused on synthetic compounds, Traditional Chinese Medicines (TCM),combinations of synthetic compounds and TCM (CST), biological products and medical apparatus. The anti-allergy patents in China mainly focus on well-known targets, such as histamine receptor and leukotrienes, which consist of 93% of patents for validated targets. Approximately 93% targeting diseases are bronchial asthma, allergic rhinitis and atopic dermatitis. Our analyzing results indicate that there are great opportunities for application of patents on development of novel anti-allergic compounds and modernization of TCM in China.
近几十年来，过敏性疾病的患病率急剧上升。持有专利是保护优质抗过敏产品的手段之一。然而，中国抗过敏专利的情况鲜为人知。本文总结并分析了1988年1月至2008年9月在中国发布的抗过敏专利。在这20年中，中国共授予了789项抗过敏专利。中国、欧洲国家、美国、日本和其他国家分别拥有这些抗过敏专利总数的44%、21%、19%、12%和4%。有趣的是，授予中国人的抗过敏专利中有88%由平民持有，而授予外国人的专利绝大多数由制药公司持有。所有抗过敏专利都集中在合成化合物、中药、合成化合物与中药的组合（CST）、生物制品和医疗器械上。中国的抗过敏专利主要集中在知名靶点上，如组胺受体和白三烯，它们占已验证靶点专利的93%。约93%的靶向疾病是支气管哮喘、过敏性鼻炎和特应性皮炎。我们的分析结果表明，在中国，新型抗过敏化合物开发和中药现代化的专利应用有很大机会。
Zotero 插件